References
- Bharti S, Rani N, Krishnamurthy B, et al. Preclinical evidence for the pharmacological actions of naringin: a review. Planta Med. 2014;80:437–451.
- Commission CP. Chinese Pharmacopoeia. Beijing: China Medical Science Press; 2015.
- Chen R, Qi Q-L, Wang M-T, et al. Therapeutic potential of naringin: an overview. Pharm Biol. 2016;54:3203–3210.
- Liu M, Yang C, Zou W, et al. Toxicokinetics of naringin, a putative antitussive, after 184-day repeated oral administration in rats. Environ Toxicol Pharmacol. 2011;31:485–489.
- Li P, Wang S, Guan X, et al. Acute and 13weeks subchronic toxicological evaluation of naringin in Sprague-Dawley rats. Food Chem Toxicol. 2013;60:1–9.
- Li P, Wang S, Guan X, et al. Six months chronic toxicological evaluation of naringin in Sprague–Dawley rats. Food Chem Toxicol. 2014;66:65–75.
- Chen F, Zhang N, Ma X, et al. Naringin alleviates diabetic kidney disease through inhibiting oxidative stress and inflammatory reaction. PLoS One 2015;10:e0143868.
- You Q, Wu Z, Wu B, et al. Naringin protects cardiomyocytes against hyperglycemia-induced injuries in vitro and in vivo. J Endocrinol. 2016;230:197–214.
- Zhang J, Yang S, Li H, et al. Naringin ameliorates diabetic nephropathy by inhibiting NADPH oxidase 4. Eur J Pharmacol. 2017;804:1–6.
- Wei M, Yang Z, Li P, et al. Anti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model. Am J Chin Med. 2007;35:663–667.
- Ang ES, Yang X, Chen H, et al. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation. FEBS Lett. 2011;585:2755–2762.
- Li N, Jiang Y, Wooley PH, et al. Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. J Orthopaed Sci. 2013;18:478–485.
- Li N, Xu Z, Wooley PH, et al. Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments. Drug Des, Dev Therapy 2014;8:1–11.
- Li FB, Sun XL, Ma JX, et al. Effect of naringin on osteoclast differentiation. Chin J Chin Meter Med. 2015;40:308–312.
- Ma X, Lv J, Sun X, et al. Naringin ameliorates bone loss induced by sciatic neurectomy and increases Semaphorin 3A expression in denervated bone. Sci Rep. 2016;6:24562
- Liu M, Li Y, Yang ST. Effects of naringin on the proliferation and osteogenic differentiation of human amniotic fluid-derived stem cells. J Tissue Eng Regen Med. 2017;11:276–284.
- Dong D, Xu L, Yin L, et al. Naringin prevents carbon tetrachloride-induced acute liver injury in mice. J Funct Foods 2015;12:179–191.
- Manna K, Khan A, Biswas S, et al. Naringin ameliorates radiation-induced hepatic damage through modulation of Nrf2 and NF-κB pathways. RSC Adv. 2016;6:23058–23073.
- Gao S, Li P, Yang H, et al. Antitussive effect of naringin on experimentally induced cough in Guinea pigs. Planta Med. 2011;77:16–21.
- Luo Y-L, Zhang C-C, Li P-B, et al. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. Int Immunopharmacol. 2012;13:301–307.
- Jiao H-y, Su W-w, Li P-b, et al. Therapeutic effects of naringin in a guinea pig model of ovalbumin-induced cough-variant asthma. Pulmonary Pharmacol Therapeutics 2015;33:59–65.
- Kumar A, Prakash A, Dogra S. Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by d-galactose in mice. Food Chem Toxicol. 2010;48:626–632.
- Chtourou Y, Gargouri B, Kebieche M, et al. Naringin abrogates cisplatin-induced cognitive deficits and cholinergic dysfunction through the down-regulation of AChE expression and iNOS signaling pathways in hippocampus of aged rats. J Mol Neurosci. 2015;56:349–362.
- Chen K-Y, Lin K-C, Chen Y-S, et al. A novel porous gelatin composite containing naringin for bone repair. Evi-Based Complement Altern Med. 2013;2013:1.
- Ji Y, Wang L, Watts DC, et al. Controlled-release naringin nanoscaffold for osteoporotic bone healing. Dent Mater. 2014;30:1263–1273.
- Fang T, Wang Y, Ma Y, et al. A rapid LC/MS/MS quantitation assay for naringin and its two metabolites in rats plasma. J Pharm Biomed Anal. 2006;40:454–459.
- Li X, Xiong Z, Lu S, et al. Pharmacokinetics of naringin and its metabolite naringenin in rats after oral administration of Rhizoma Drynariae extract assayed by UPLC-MS/MS. Chin J Nat Med. 2010;8:40–46.
- Mielczarek C. Acid–base properties of selected flavonoid glycosides. Eur J Pharm Sci. 2005;25:273–279.
- Ficarra R, Tommasini S, Raneri D, et al. Study of flavonoids/β-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J Pharm Biomed Anal. 2002;29:1005–1014.
- Feng T, Wang K, Liu F, et al. Structural characterization and bioavailability of ternary nanoparticles consisting of amylose, α-linoleic acid and β-lactoglobulin complexed with naringin. Int J Biol Macromol. 2017;99:365–374.
- Sekiguchi K, Obi N. Studies on absorption of eutetic mixture. I. A comparison of the behavior of eutetic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1996;9:866–872.
- Huang Y, Dai W-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharmaceutica Sinica B 2014;4:18–25.
- Xu YR, Zhang KF, Xie QJ, et al. Chemical constituents from young fruits of Citrus maxima cv.Shatian. J Chin Med Mater. 2015;38:1879–1881.
- Alam MA, Ali R, Al-Jenoobi FI, et al. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates. Exp Opin Drug Deliv. 2012;9:1419–1440.